Trial Update

Novartis: Farabursen Phase 3 Start Still Planned for 2026

Novartis's Q3 2026 update shows the farabursen Phase 3 had not dosed its first patient by September 30, but the start remains a planned 2026 milestone.

Novartis's Q3 2026 investor presentation, published October 27, lists 'Farabursen ADPKD – PhIII FPFV' (first patient, first visit) among its key study starts planned for the second half of 2026. Other programs on the same slide are marked as started, but the farabursen entry has no status yet, meaning the first patient had not been dosed by the end of September.

As of late October 2026, the Phase 3 has not appeared on ClinicalTrials.gov or the EU Clinical Trials Information System. Novartis still lists farabursen (CYX082, a miR-17 inhibitor) in its Phase 1 pipeline table, which reflects the completed Phase 1b rather than any setback.

We have heard community reports that recruitment is starting. Nephrology centres often begin identifying candidates before a trial is publicly listed, so those reports may reflect site preparation. We will update the pipeline as soon as a registry entry or company announcement confirms the trial is open.

Farabursen remains the most closely watched drug in the ADPKD pipeline after its Phase 1b, in which kidney growth was effectively halted (0.05% vs 2.58% on placebo).

Related Drugs in Pipeline

View all drugs in our PKD drug pipeline tracker.

Source

Novartis Q3 2026 Investor Presentation
farabursen novartis phase-3 anti-miR-17 trial-update

Disclaimer: This information is for educational purposes only and is not medical advice. News articles are based on publicly available data from ClinicalTrials.gov, company press releases, and published research. Consult your nephrologist before making treatment decisions.

Stay Updated on PKD Research

Get notified when new drugs enter clinical trials, trial results are published, or approved treatments change.

No spam. Unsubscribe anytime.